Advanced Leuprorelin Synthesis Method Enhancing Commercial Scalability And Purity Standards

The pharmaceutical industry continuously seeks robust manufacturing pathways for complex peptide therapeutics, and patent CN114014912B introduces a transformative approach for producing leuprorelin. This specific intellectual property details a method for preparing leuprorelin by combining solid phase and liquid phase synthesis techniques, addressing critical bottlenecks in traditional polypeptide manufacturing. The core innovation lies in the development of a specialized liquid phase carrier obtained by reacting 3-ethoxy-4-hydroxybenzaldehyde and 2-(2-ethoxyphenoxy) bromoethane in DMF containing potassium carbonate. By utilizing this carrier for fragment synthesis in the liquid phase before transitioning to solid phase resin, the process effectively mitigates the instability issues often encountered in all-solid-phase coupling. This hybrid strategy not only ensures the successful preparation of leuprorelin but also guarantees a significant improvement in synthesis yield and product consistency. For global supply chain stakeholders, this represents a viable pathway to secure high-purity peptide intermediates with enhanced commercial feasibility. The technical breakthroughs outlined in this patent provide a foundation for reliable leuprorelin supplier partnerships focused on quality and scalability.

The Limitations of Conventional Methods vs. The Novel Approach

The Limitations of Conventional Methods

Traditional solid-phase synthesis methods for synthesizing leuprorelin typically involve connecting all amino acids from the carbon end followed by cleavage using ethylamine liquid. However, this cutting off by using liquid ethylamine needs to be carried out at low temperature under pressure sealing, which creates substantial operational challenges for industrial production. The requirement for low-temperature pressure sealing is inconvenient in industrial production and is difficult to produce on a large scale due to equipment constraints and safety risks. Furthermore, all-solid-phase coupling often suffers from instability of products during the extended synthesis cycles, leading to lower synthesis yield and increased formation of impurities. The difficulty to produce on a large scale means that supply continuity can be compromised when demand surges, affecting the reliability of the supply chain for downstream pharmaceutical manufacturers. These inherent limitations necessitate a technological shift towards more flexible and robust synthesis strategies that can accommodate commercial scale-up of complex peptide intermediates without compromising safety or quality standards.

The Novel Approach

The novel approach disclosed in the patent utilizes a liquid phase carrier to carry out fragment synthesis in a liquid phase before combining the product with solid phase resin. Synthesizing the fragment to obtain an Fmoc-Arg-Pro-O-liquid phase carrier allows for better control over the critical initial coupling steps where side reactions are most prevalent. Removing the liquid phase carrier from the product obtained in the step and combining it with solid phase resin enables the subsequent coupling of amino acid reagents according to the sequence of amino acid sequences in leuprorelin to obtain leuprorelin-based polypeptide resin. This method successfully avoids diketopiperazine side reactions and combines the defect of long liquid phase synthesis time with the advantage of rapid solid phase synthesis. The leuprorelin-based polypeptide is separated after the leuprorelin-based polypeptide resin is cut, and then the leuprorelin is obtained after ethylation treatment under much milder conditions. This strategic combination ensures that the yield of leuprorelin is ensured while facilitating cost reduction in peptide manufacturing through simplified downstream processing.

Mechanistic Insights into Hybrid Solid-Liquid Phase Synthesis

The mechanistic foundation of this process relies on the precise construction of the liquid phase carrier using sodium borohydride reduction following the initial condensation reaction. In the preparation of the liquid phase carrier, potassium carbonate is added into DMF, then 3-ethoxy-4-hydroxybenzaldehyde and 2-(2-ethoxyphenoxy) bromoethane are added, nitrogen protection is performed, stirring reaction is performed for 18-48h at the temperature of 60-80 ℃. The resulting benzaldehyde compound is then reduced by using a reducing agent, wherein the reducing agent is sodium borohydride, to form the stable linker required for fragment assembly. Adding benzaldehyde compounds into tetrahydrofuran solution under the protection of nitrogen, adding sodium borohydride, stirring and reacting at the temperature of 30-50 ℃ for 2-10h ensures complete conversion to the alcohol functionality needed for loading. This careful control of reaction conditions prevents premature degradation of the carrier and ensures high loading efficiency for the subsequent amino acid coupling steps. The use of specific solvents like DMF and tetrahydrofuran optimizes solubility and reaction kinetics, which is critical for maintaining high-purity leuprorelin standards throughout the synthesis.

Impurity control is achieved through the strategic separation of the liquid phase carrier from the Fmoc-Arg-Pro-O-liquid phase carrier before solid phase attachment. The Fmoc-Arg-Pro-O-liquid carrier is prepared from Fmoc-Arg(Pbf)-OSu and Fmoc-Pro-O-liquid carrier, ensuring that the critical Arg-Pro dipeptide fragment is formed with minimal racemization. Removing the liquid phase carrier from the Fmoc-Arg-Pro-O-liquid phase carrier eliminates soluble byproducts that could otherwise contaminate the solid phase resin and complicate purification. The solid phase resin is any one of Wang resin and Rink-Amide-AM resin, providing a stable anchor for the elongation of the remaining peptide sequence. The amino acid reagent is activated for 3-30 min by DMF solution containing HOBt, DIC, which minimizes the formation of deletion sequences and other common peptide synthesis impurities. The coupling sequence of the amino acid reagents is Fmoc-Leu-OH, Fmoc-D-Leu-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Trp(Boc)-OH, Fmoc-His(Trt)-OH, H-Pyr-OH, ensuring strict adherence to the target sequence. This rigorous control over each coupling step results in the high purity levels observed in the experimental data, such as the 99.83% purity achieved in Example 3.

How to Synthesize Leuprorelin Efficiently

The synthesis of leuprorelin via this hybrid method requires strict adherence to the patented protocol to maximize yield and minimize impurities. The process begins with the preparation of the liquid phase carrier, followed by the assembly of the Arg-Pro fragment in solution before loading onto the solid support. Detailed operational parameters regarding temperature, solvent ratios, and reaction times are critical for reproducing the high yields reported in the patent examples. Operators must ensure nitrogen protection is maintained during sensitive steps to prevent oxidation of reagents and intermediates. The transition from liquid phase fragment synthesis to solid phase elongation must be managed carefully to ensure quantitative loading onto the resin. For a comprehensive understanding of the specific operational steps and safety precautions, please refer to the standardized synthesis guide provided below. This guide encapsulates the critical process parameters necessary for successful implementation in a GMP environment.

1. Prepare the liquid phase carrier by reacting 3-ethoxy-4-hydroxybenzaldehyde with 2-(2-ethoxyphenoxy) bromoethane in DMF containing potassium carbonate.
2. Synthesize the Fmoc-Arg-Pro-O-liquid phase carrier fragment and couple it to solid phase resin such as Wang resin.
3. Complete the amino acid sequence coupling, cleave the peptide resin, and perform ethylation treatment to obtain final leuprorelin.

Commercial Advantages for Procurement and Supply Chain Teams

This patented synthesis route offers substantial benefits for procurement and supply chain teams focused on cost reduction in peptide manufacturing and supply continuity. By eliminating the need for low-temperature pressure sealing during the cleavage step, the process significantly reduces the complexity and cost of the required manufacturing equipment. The avoidance of diketopiperazine side reactions means less material is wasted during synthesis, leading to substantial cost savings in raw material consumption. The ability to synthesize the critical fragment in the liquid phase allows for better quality control before committing to the solid phase, reducing the risk of batch failures. Enhanced supply chain reliability is achieved through a process that is easier to scale and less dependent on specialized high-pressure equipment. The simplified ethylation treatment further reduces processing time and energy consumption, contributing to a more sustainable and efficient manufacturing workflow. These factors collectively support reducing lead time for high-purity peptide intermediates and ensure a stable supply for downstream drug product manufacturing.

• Cost Reduction in Manufacturing: The elimination of expensive high-pressure low-temperature equipment for cleavage directly lowers capital expenditure and maintenance costs for production facilities. Removing the need for specialized pressure sealing operations simplifies the workflow and reduces the labor intensity associated with hazardous chemical handling. The improved yield stability means that less starting material is required to produce the same amount of final product, optimizing raw material utilization. Furthermore, the simplified purification process resulting from higher crude purity reduces the consumption of chromatography resins and solvents. These cumulative efficiencies drive down the overall cost of goods sold without compromising the quality standards required for pharmaceutical intermediates.
• Enhanced Supply Chain Reliability: The robustness of the hybrid synthesis method ensures consistent batch-to-batch performance, which is critical for maintaining supply continuity for global clients. The use of commonly available solvents and reagents reduces the risk of supply disruptions associated with specialized or scarce chemicals. The scalability of the liquid phase fragment synthesis allows for flexible production scheduling to meet fluctuating demand patterns. Additionally, the milder reaction conditions reduce the risk of safety incidents that could otherwise halt production lines. This reliability makes the manufacturer a reliable leuprorelin supplier capable of meeting strict delivery commitments even during market volatility.
• Scalability and Environmental Compliance: The process is designed for commercial scale-up of complex peptide intermediates, allowing for seamless transition from pilot to full-scale production. The reduction in hazardous waste generation from simplified cleavage and purification steps supports stricter environmental compliance regulations. Lower solvent consumption and energy usage contribute to a reduced carbon footprint for the manufacturing process. The ability to handle larger batch sizes without proportional increases in complexity supports economies of scale. This scalability ensures that the supply can grow alongside the market demand for leuprorelin-based therapies without requiring disproportionate infrastructure investments.

Frequently Asked Questions (FAQ)

The following questions and answers are derived directly from the technical specifications and beneficial effects described in the patent documentation. They address common concerns regarding the feasibility, safety, and quality implications of adopting this hybrid synthesis method. Understanding these details is crucial for technical teams evaluating the integration of this process into their existing manufacturing workflows. The answers reflect the specific advantages related to yield improvement, impurity control, and operational safety highlighted in the patent examples. Clients are encouraged to review these insights to assess the alignment with their specific quality and production requirements.

Q: How does the hybrid solid-liquid phase method improve leuprorelin yield?

A: The hybrid method avoids diketopiperazine side reactions common in all-solid-phase synthesis and eliminates the need for low-temperature pressure sealing during cleavage, resulting in higher overall yields and purity.

Q: What are the scalability advantages of this liquid phase carrier?

A: The liquid phase carrier allows for fragment synthesis in solution where reaction monitoring is easier, facilitating smoother scale-up from laboratory to commercial production without the mechanical limitations of pure solid-phase reactors.

Q: Is the ethylation treatment process safe for industrial production?

A: Yes, the patented method performs ethylation treatment under moderate conditions using ethylamine and DIC, avoiding the hazardous low-temperature pressure sealing required by traditional solid-phase cleavage methods.

Partnering with NINGBO INNO PHARMCHEM: Your Reliable Leuprorelin Supplier

NINGBO INNO PHARMCHEM stands ready to leverage this advanced synthesis technology to deliver high-purity leuprorelin for your pharmaceutical needs. As a CDMO expert, we possess extensive experience scaling diverse pathways from 100 kgs to 100 MT/annual commercial production, ensuring that your supply needs are met with precision. Our facilities are equipped with stringent purity specifications and rigorous QC labs to guarantee that every batch meets the highest international standards. We understand the critical nature of peptide intermediates in the drug development lifecycle and are committed to supporting your projects with technical excellence. Our team is dedicated to maintaining the integrity of the synthesis process to deliver consistent quality and performance.

We invite you to engage with our technical procurement team to discuss how this patented method can benefit your specific supply chain. Request a Customized Cost-Saving Analysis to understand the potential economic impact of adopting this hybrid synthesis route. Our experts are available to provide specific COA data and route feasibility assessments tailored to your project requirements. Partnering with us ensures access to cutting-edge technology and a commitment to long-term supply stability. Contact us today to initiate a dialogue about securing your leuprorelin supply with confidence and reliability.